73 related articles for article (PubMed ID: 16711549)
1. [Molecular hemato-oncology and new specific treatment strategies for leukemia].
Martínez-Mancilla M; Zafra-de la Rosa G; Reynoso-Gómez E; Astudillo-de la Vega H; Nambo-Lucio Mde J; Benítez-Bribiesca L; Martínez-Avalos A; Rivera-Luna R; Gariglio P
Gac Med Mex; 2006; 142(2):145-50. PubMed ID: 16711549
[TBL] [Abstract][Full Text] [Related]
2. A closer look at specific therapeutic strategies in leukemia.
Martinez-Mancilla M; Zafra G; Reynoso-Gómez E; Martinez-Avalos A; Rivera-Luna R; Gariglio P
Leuk Lymphoma; 2004 Sep; 45(9):1767-73. PubMed ID: 15223634
[TBL] [Abstract][Full Text] [Related]
3. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
Lee SM; Bae JH; Kim MJ; Lee HS; Lee MK; Chung BS; Kim DW; Kang CD; Kim SH
J Pharmacol Exp Ther; 2007 Sep; 322(3):1084-92. PubMed ID: 17569822
[TBL] [Abstract][Full Text] [Related]
4. Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.
Hu J; Zhou GB; Wang ZY; Chen SJ; Chen Z
Adv Cancer Res; 2007; 98():191-220. PubMed ID: 17433911
[TBL] [Abstract][Full Text] [Related]
5. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
6. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
7. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
8. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
[TBL] [Abstract][Full Text] [Related]
9. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid receptors, hematopoiesis and leukemogenesis.
Collins SJ
Curr Opin Hematol; 2008 Jul; 15(4):346-51. PubMed ID: 18536573
[TBL] [Abstract][Full Text] [Related]
11. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
[TBL] [Abstract][Full Text] [Related]
12. Trans-repressive effect of NUP98-PMX1 on PMX1-regulated c-FOS gene through recruitment of histone deacetylase 1 by FG repeats.
Bai XT; Gu BW; Yin T; Niu C; Xi XD; Zhang J; Chen Z; Chen SJ
Cancer Res; 2006 May; 66(9):4584-90. PubMed ID: 16651408
[TBL] [Abstract][Full Text] [Related]
13. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
14. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
16. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
18. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
19. Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction.
Piazza F; Semenzato G
Expert Rev Anticancer Ther; 2004 Jun; 4(3):387-400. PubMed ID: 15161438
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylases--an important class of cellular regulators with a variety of functions.
Hildmann C; Riester D; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]